# World Intellectual Property Organization





#### (43) International Publication Date 16 October 2003 (16.10.2003)

International Bureau

### PCT

## (10) International Publication Number WO 03/084941 A2

C07D 295/18, (51) International Patent Classification<sup>7</sup>: 241/24, 211/60, 207/16, A61K 31/40, 31/44, 31/535, A61P 29/00

Basel (CH). NEUMANN, Ulf [DE/CH]; Waldhofstrasse 62, CH-4310 Rheinfelden (CH).

PCT/EP03/03644 (21) International Application Number:

(74) Agent: GROS, Florent; Novartis AG, Corporate Intellectual Property, CH-4002 Basel (CH).

(22) International Filing Date: 8 April 2003 (08.04.2003)

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SE, SG, SK, TJ, TM, TN, TR,

TT, UA, US, UZ, VC, VN, YU, ZA, ZW.

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 0208176.8

9 April 2002 (09.04.2002)

(71) Applicant (for all designated States except AT, US): NO-VARTIS AG [CH/CH]; Lichtstrasse 35, CH-4056 Basel (84) Designated States (regional): Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR).

(71) Applicant (for AT only): NOVARTIS PHARMA GMBH [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).

#### Published:


(72) Inventors; and

without international search report and to be republished upon receipt of that report

(75) Inventors/Applicants (for US only): JANSER, Philipp [CH/CH]; Delsbergerallee 1, CH-4053 Basel (CH). MILTZ, Wolfgang [DE/CH]; Tessinstrasse 12, CH-4054

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: HYDROXAMIC ACID DERIVATIVES



(57) Abstract: Novel hydroxamic acid derivatives, e.g., of formula (I), wherein R1, R2, R3 and R4 are as defined, are found to be useful as pharmaceuticals, e.g., for the suppression of TNF release and the treatment of autoimmune and inflammatory diseases, e.g., multiple sclerosis and rheumatoid arthritis. Methods of making the compounds, novel intermediates, and pharmaceutical compositions comprising the compounds are provided.